Weerawat Manosuthi

Summary

Publications

  1. ncbi request reprint Declining prevalence of drug-resistant tuberculosis among HIV/tuberculosis co-infected patients receiving antiretroviral therapy
    Somnuek Sungkanuparph
    Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Rama 6 Rd, Bangkok 10400, Thailand
    J Med Assoc Thai 90:884-8. 2007
  2. doi request reprint Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study
    Weerawat Manosuthi
    Department of Medicine, Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand
    J Acquir Immune Defic Syndr 60:377-83. 2012
  3. ncbi request reprint ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi 11000, Thailand
    J Antimicrob Chemother 69:2195-201. 2014
  4. doi request reprint CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand Electronic address
    Int J Antimicrob Agents 43:292-6. 2014
  5. pmc Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Thailand
    Antimicrob Agents Chemother 57:1019-24. 2013
  6. ncbi request reprint Clinical characteristics and treatment outcomes among patients with tuberculosis in Bangkok and Nonthaburi, Thailand
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand
    Southeast Asian J Trop Med Public Health 43:1426-36. 2012
  7. doi request reprint HIV-1 drug resistance-associated mutations among antiretroviral-naive Thai patients with chronic HIV-1 infection
    Weerawat Manosuthi
    Department of Medicine, Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand
    J Med Virol 85:194-9. 2013
  8. pmc Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi 11000, Thailand
    AIDS Res Ther 9:8. 2012
  9. pmc Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, 11000, Thailand
    AIDS Res Ther 6:30. 2009
  10. pmc Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand
    BMC Infect Dis 7:14. 2007

Collaborators

Detail Information

Publications70

  1. ncbi request reprint Declining prevalence of drug-resistant tuberculosis among HIV/tuberculosis co-infected patients receiving antiretroviral therapy
    Somnuek Sungkanuparph
    Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Rama 6 Rd, Bangkok 10400, Thailand
    J Med Assoc Thai 90:884-8. 2007
    ..Antiretroviral therapy (ART) has been more accessible in these countries. The present study aimed to determine the impact of ART on the prevalence of DR-TB among HIV/TB co-infected patients...
  2. doi request reprint Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study
    Weerawat Manosuthi
    Department of Medicine, Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand
    J Acquir Immune Defic Syndr 60:377-83. 2012
    ..Optimal timing for initiation of antiretroviral therapy (ART) among HIV-infected patients with tuberculosis (TB) is not well established...
  3. ncbi request reprint ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi 11000, Thailand
    J Antimicrob Chemother 69:2195-201. 2014
    ..To study the correlations of genetic variants of tenofovir tubular transporters, plasma tenofovir concentrations and clinical factors with decreased glomerular filtration rate in HIV-infected patients who received tenofovir...
  4. doi request reprint CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand Electronic address
    Int J Antimicrob Agents 43:292-6. 2014
    ..05). In summary, HIV-infected patients with the pharmacogenetic marker 'CYP2B6 haplotype *6/*6' may have increased susceptibility to hepatotoxicity with efavirenz-based ART...
  5. pmc Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Thailand
    Antimicrob Agents Chemother 57:1019-24. 2013
    ..084, P = 0.027) and high body weight (beta = -0.076, P = 0.002). In conclusion, pharmacogenetic markers of CYP2B6 have the greatest impact with respect to inducing low plasma efavirenz concentrations in HIV/TB Thai patients...
  6. ncbi request reprint Clinical characteristics and treatment outcomes among patients with tuberculosis in Bangkok and Nonthaburi, Thailand
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand
    Southeast Asian J Trop Med Public Health 43:1426-36. 2012
    ..The percent of patients with unfavorable outcomes was relatively high, particularly among HIV co-infected and elderly subjects. Further effort needs to be made to improve these unfavorable TB outcomes in Nonthaburi and Bangkok, Thailand...
  7. doi request reprint HIV-1 drug resistance-associated mutations among antiretroviral-naive Thai patients with chronic HIV-1 infection
    Weerawat Manosuthi
    Department of Medicine, Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand
    J Med Virol 85:194-9. 2013
    ..HIV-1 DRAMs, especially to NNRTIs, are emerging in a middle-income country after widespread use of NNRTI-based ART. HIV genotypic assays before ART initiation in patients with chronic HIV-1 infection should be considered...
  8. pmc Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi 11000, Thailand
    AIDS Res Ther 9:8. 2012
    ..abstract:..
  9. pmc Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, 11000, Thailand
    AIDS Res Ther 6:30. 2009
    ....
  10. pmc Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand
    BMC Infect Dis 7:14. 2007
    ..The clinical data of plasma NVP level, safety and efficacy of antiretroviral therapy (ART) for the concurrent use of nevirapine (NVP)-based ART and fluconazole (FLU) is scanty...
  11. doi request reprint Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study
    Weerawat Manosuthi
    Department of Medicine, Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Tiwanon Road, Nonthaburi 11000, Thailand
    Int J Infect Dis 14:e1013-7. 2010
    ..Long-term outcomes of this concurrent treatment are unknown...
  12. ncbi request reprint Case report: Brucellosis: a re-emerging disease in Thailand
    Weerawat Manosuthi
    Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand
    Southeast Asian J Trop Med Public Health 35:109-12. 2004
    ..This clinical syndrome should be included in the differential diagnosis of patients presenting with prolonged fever, particularly those with contact to animals which could serve as reservoirs...
  13. pmc Monitoring and impact of fluconazole serum and cerebrospinal fluid concentration in HIV-associated cryptococcal meningitis-infected patients
    W Manosuthi
    Department of Medicine, Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand
    HIV Med 11:276-81. 2010
    ..The aim of the present study was to assess fluconazole pharmacokinetic measures in serum and cerebrospinal fluid (CSF); and the correlation of these measures with clinical outcomes of invasive fungal infections...
  14. doi request reprint Clinical case definition and manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand
    AIDS 23:2467-71. 2009
    ..The performance of this definition and clinical manifestations of TB-IRIS were studied...
  15. pmc Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin
    Weerawat Manosuthi
    Department of Medicine, Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi 11000, Thailand
    Antimicrob Agents Chemother 53:4545-8. 2009
    ..5 +/- 2.7 mg/liter, respectively. High body weight was associated with a low efavirenz C12 at weeks 6 and 12 (P = 0.003, r = -0.255). The efavirenz C12 regression prediction line at 1 mg/liter intercepted a mean body weight of 57.5 kg...
  16. pmc Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand
    AIDS Res Ther 7:37. 2010
    ..However, knowledge regarding whether there is any difference of the frequency of renal injury between tenofovir/lamivudine/efavirenz and tenofovir/lamivudine/nevirapine is lacking...
  17. doi request reprint Single-Boosted Protease Inhibitor versus Double-Boosted Protease Inhibitors for the Salvage Therapy in HIV-Infected Patients
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
    J Int Assoc Physicians AIDS Care (Chic) 10:105-10. 2011
    ....
  18. ncbi request reprint Concurrent chromomycosis and aspergillosis of the maxillary sinus
    Weerawat Manosuthi
    Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand
    J Med Assoc Thai 87:1112-5. 2004
    ..The patient responded to a combination therapy of surgical excision and antifungal agent...
  19. ncbi request reprint Chronic neck ulcer in an immunocompetent host
    Weerawat Manosuthi
    Department of Medicine, Ramathibodi Hospital, Mahidol University, 270 Rama 6 Road, Bangkok 10400, Thailand
    Lancet Infect Dis 5:190. 2005
  20. pmc Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study
    Weerawat Manosuthi
    Bamrasnaradura Institute, Ministry of Public Health, Nonthaburi, 11000, Thailand
    BMC Infect Dis 5:67. 2005
    ..To compare the adverse events after initiation of NVP-based ART among HIV-infected patients who did not receive fluconazole (group A), received fluconazole 400 mg/week (group B), and received fluconazole 200 mg/day (group C)...
  21. ncbi request reprint Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin
    Weerawat Manosuthi
    Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
    AIDS 19:1481-6. 2005
    ..Concomitant use of efavirenz and rifampicin is common for treatment of HIV and tuberculosis. Plasma efavirenz levels can be reduced by rifampicin, but the appropriate daily dosage of efavirenz is unclear...
  22. ncbi request reprint Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis
    Weerawat Manosuthi
    Bamrasnaradura Institute, Ministry of Public Health, Nonthaburi, Thailand
    J Med Assoc Thai 89:795-802. 2006
    ..neoformans) obtained from the CerebroSpinal Fluid (CSF); and clinical outcomes of HIV-infected patients diagnosed with cryptococcal meningitis...
  23. ncbi request reprint Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash
    W Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand
    HIV Med 7:378-82. 2006
    ..To determine the incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash...
  24. ncbi request reprint Renal impairment in HIV-1 infected patients receiving antiretroviral regimens including tenofovir in a resource-limited setting
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand
    Southeast Asian J Trop Med Public Health 42:643-50. 2011
    ..This report highlights the potentially irreversible adverse effect of this agent, particularly in patients with vulnerable kidneys and concomitant use of tenofovir and boosted PI...
  25. pmc Protease polymorphisms in HIV-1 subtype CRF01_AE represent selection by antiretroviral therapy and host immune pressure
    Weerawat Manosuthi
    University of California San Diego, La Jolla, California, USA
    AIDS 24:411-6. 2010
    ..We investigated the effect of protease resistance-associated mutations (PRAMs) and population-based HLA haplotype frequencies on polymorphisms found in CRF01_AE pro...
  26. doi request reprint A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study
    Weerawat Manosuthi
    Dept of Medicine, Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Tiwanon Rd, Nonthaburi 11000, Thailand
    Clin Infect Dis 48:1752-9. 2009
    ....
  27. ncbi request reprint Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results
    Weerawat Manosuthi
    Bamrasnaradura Institute, Ministry of Public Health, Nonthaburi, Thailand
    AIDS 20:131-2. 2006
    ..We report the similar virological and immunological outcomes at 48 weeks between the two groups. Efavirenz 600 mg/day should be sufficient for concurrent use with rifamipicin...
  28. pmc Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, 11000, Thailand
    BMC Infect Dis 8:136. 2008
    ..To date, data on the durability of a regimen of stavudine, lamivudine and nevirapine are very limited, particularly from the resource-limited settings...
  29. ncbi request reprint Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL
    Weerawat Manosuthi
    Department of Medicine, Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Tiwanon Road, Nonthaburi 11000, Thailand
    Int J STD AIDS 18:782-6. 2007
    ..Despite the low baseline in this population, the higher number of baseline CD4 cells is continuously associated with a higher risk for skin rashes...
  30. ncbi request reprint Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand
    J Med Assoc Thai 91:159-65. 2008
    ..To determine incidence and risk factors of nevirapine (NVP)-associated severe hepatitis that led to NVP discontinuation among HIV-infected patients with CD4 < 250 cells/microL...
  31. ncbi request reprint Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting
    Somnuek Sungkanuparph
    Department of Medicine, Ministry of Public Health, Nonthaburi, Thailand
    Curr HIV Res 6:474-6. 2008
    ..This strategy may be an option for patients who cannot afford or tolerate protease inhibitor. Prospective study to evaluate this strategy should be conducted in resource-limited setting...
  32. ncbi request reprint Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, 11000, Thailand
    Clin Infect Dis 43:253-5. 2006
    ..Mean plasma nevirapine levels at 8 and 12 weeks were lower in patients receiving rifampicin (P=.048). However, virological and immunological outcomes at 24 weeks were not different between the 2 groups (P>.05)...
  33. ncbi request reprint Influence of ABCB-1 C3435T polymorphisms on plasma nevirapine and efavirenz levels and their effects on virologic and immunological outcomes in HIV/TB co-infected Thai adults under anti-retroviral therapy
    Sumonmal Uttayamakul
    Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    Southeast Asian J Trop Med Public Health 43:78-88. 2012
    ....
  34. ncbi request reprint Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, 11000, Thailand
    Clin Infect Dis 44:141-4. 2007
    ..There was no statistically significant difference in 60-week antiviral efficacy between these patients and patients receiving nevirapine-based antiretroviral therapy alone (P>.05)...
  35. doi request reprint Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting
    Krittaecho Siripassorn
    Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand
    AIDS Res Hum Retroviruses 26:139-48. 2010
    ..In the subgroup analysis, patients who received double-boosted PIs demonstrated a superior immunological response but not better virological outcomes compared to the single-boosted PI +/- OBR group...
  36. doi request reprint Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine
    Somnuek Sungkanuparph
    Division of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama 6 Road, Bangkok 10400, Thailand
    J Clin Virol 41:310-3. 2008
    ..K65R mutations that occur after failing this regimen prevent the use of tenofovir, didanosine, and abcavir in the second-line regimen...
  37. ncbi request reprint Virological and immunological responses of efavirenz-based HAART regimen initiated in HIV-infected patients at CD4 < 100 versus CD4 > or = 100 cells/mm3
    Sasisopin Kiertiburanakul
    Division of lnfectious Diseases, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
    J Med Assoc Thai 89:1381-7. 2006
    ..To compare virological and immunological responsiveness of efavirenz (EFV)-based highly active anti retroviral therapy (HAART) between patients with baseline CD4 < 100 and CD4 > or = 100 cells/mm3...
  38. doi request reprint Tipranavir resistance associated mutations in protease inhibitor-naïve patients with HIV-1 subtype A/E infection
    Somnuek Sungkanuparph
    Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
    J Clin Virol 43:284-6. 2008
    ..Tipranavir-resistance associated mutations (TPV-RAMs) are often observed among patients with HIV-1 subtype A/E infection. Data regarding TPV resistance in subtype A/E is still limited...
  39. doi request reprint Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy
    Pawinee Wongprasit
    Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
    AIDS Patient Care STDS 24:205-9. 2010
    ..Positive HBeAg and longer duration of lamivudine use are risk factors for HBV-DR. In addition to lamivudine resistance, cross-resistance to other anti-HBV drugs is also frequently observed...
  40. ncbi request reprint Tenofovir resistance among HIV-infected patients failing a fixed-dose combination of stavudine, lamivudine, and nevirapine in a resource-limited setting
    Somnuek Sungkanuparph
    Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
    AIDS Patient Care STDS 21:711-4. 2007
  41. ncbi request reprint Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi 11000, Thailand
    J Infect 55:464-9. 2007
    ..To study incidence, risk factors, and impact of major opportunistic infections (OIs) after initiation of antiretroviral therapy (ART)...
  42. ncbi request reprint Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails
    Somnuek Sungkanuparph
    Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
    Clin Infect Dis 44:447-52. 2007
    ..Virological failure with this regimen has become more common, and a second-line regimen needs to be prepared in the national program...
  43. ncbi request reprint Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008
    Somnuek Sungkanuparph
    Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand
    J Med Assoc Thai 91:1925-35. 2008
    ....
  44. doi request reprint Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study
    Somnuek Sungkanuparph
    Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand
    Clin Infect Dis 49:931-4. 2009
    ..No association between the timing of HAART initiation and the diagnosis of IRIS was identified. Increased baseline serum cryptococcal antigen (CrAg) titer was a risk factor for cryptococcal IRIS...
  45. ncbi request reprint Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi
    J Med Assoc Thai 90:244-50. 2007
    ..A fixed-dose combination of stavudine, lamivudine, and nevirapine (GPO-VIR) is the most affordable antiretroviral therapy (ART) regimen in Thailand. The data of nevirapine (NVP) level and efficacy of this fixed-dose combination is limited...
  46. pmc Immunologic markers as predictors of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV and tuberculosis coinfected persons in Thailand
    Hong Van Tieu
    Department of Medicine, Division of Infectious Diseases, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    AIDS Res Hum Retroviruses 25:1083-9. 2009
    ..IFN-gamma, IL-2, and IL-12 responses did not differ between TB-IRIS and no TB-IRIS subjects (p > 0.05). More research into the immunopathogenesis of TB-IRIS and diagnostic potential of cytokine markers is warranted...
  47. ncbi request reprint Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin
    Anchalee Avihingsanon
    HIV NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Antivir Ther 13:529-36. 2008
    ..We aim here to determine the appropriate dose of nevirapine (NVP) in Thai HIV-tuberculosis (TB)-coinfected patients receiving rifampicin...
  48. doi request reprint Risk factors for mortality in symptomatic hyperlactatemia among HIV-infected patients receiving antiretroviral therapy in a resource-limited setting
    Weerawat Manosuthi
    Department of Medicine, Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Tiwanon Road, Nonthaburi, 11000, Thailand
    Int J Infect Dis 12:582-6. 2008
    ..To determine the mortality rate and risk factors after experiencing symptomatic hyperlactatemia in HIV-infected patients receiving antiretroviral therapy (ART)...
  49. ncbi request reprint Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy
    Weerawat Manosuthi
    Department of Medicine, Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Tiwanon Road, Nonthaburi 11000, Thailand
    J Infect 53:357-63. 2006
    ..To determine the frequency, risk factors and mortality rate of immune reconstitution inflammatory syndrome (IRIS) of tuberculosis (TB) in patients co-infected with HIV/TB and receiving antiretroviral therapy (ART)...
  50. ncbi request reprint Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi and Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
    J Acquir Immune Defic Syndr 43:42-6. 2006
    ..The impact of antiretroviral therapy (ART) on survival among patients coinfected with HIV and tuberculosis (TB) has not been well established...
  51. ncbi request reprint Initiation of highly active antiretroviral therapy in advanced AIDS with CD4 < 50 cells/mm3 in a resource-limited setting: efficacy and tolerability
    Somnuek Sungkanuparph
    Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
    Int J STD AIDS 16:243-6. 2005
    ..Twenty two patients (13.8%) had adverse drug events and half of these had to discontinue HAART. Initiation of HAART in advanced AIDS with CD4 cell count < 50 cells/mm3 is effective, safe, and well tolerated and should not be delayed...
  52. ncbi request reprint Baseline CD4 cell counts and outcomes among adult treatment naive HIV patients after taking fixed dose combination GPO-VIR-S and GPO-VIR-Z in Thailand
    Nyan Lin Kyaw
    Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    Southeast Asian J Trop Med Public Health 44:232-43. 2013
    ..401) and virologic rebound (p=0.562) were not significantly associated with the baseline CD4 count. This study shows the outcome after onset of ART did not vary by baseline CD4 cell count...
  53. ncbi request reprint Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy
    Wiroj Mankhatitham
    Department of Medicine, Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand
    J Med Assoc Thai 95:163-9. 2012
    ..To study and compare the pattern of lipid profile changes in Thai HIV and tuberculosis (TB) co-infected patients after receiving two non-nucleoside reverse transcriptase inhibitors (NNRTIs)-based antiretroviral therapy (ART)...
  54. doi request reprint Successful viral suppression with subsequent efavirenz-based regimen in HIV-1-infected patients who stop nevirapine prior to discontinuation of the NRTI backbone
    Sukanya Chimsuntorn
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Tiwanon Road, Nonthaburi, Thailand
    J Int Assoc Physicians AIDS Care (Chic) 9:43-5. 2010
    ....
  55. ncbi request reprint Survival time of HIV-infected patients with cryptococcal meningitis
    Suthat Chottanapund
    Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    J Med Assoc Thai 90:2104-11. 2007
    ..To study survival time and risk factors of mortality among HIV-infected patients who had cryptococcal meningitis...
  56. ncbi request reprint Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen
    Wiroj Mankhatitham
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand
    Southeast Asian J Trop Med Public Health 42:651-8. 2011
    ..03; 95%CI 1.26-7.29) was an independent risk factor associated with grade 1-4 hepatotoxicity (p=0.013). Monitoring of hepatotoxicity should be considered in TB/HIV-1 co-infected patients who are infected with HCV and receiving NVP...
  57. pmc Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine
    Michele W Tang
    Division Infectious Diseases, Department of Medicine, Stanford University, California 94305, USA
    J Infect Dis 207:S70-7. 2013
    ..However, because resistance testing is rarely available in resource-limited settings, it is critical to identify the cross-resistance patterns associated with first-line stavudine failure...
  58. doi request reprint Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash
    Soranun Chantarangsu
    Department of Oral Pathology, Research Unit of Herbs and Natural Products for Dental Application, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand
    Clin Infect Dis 53:341-8. 2011
    ..We aimed to identify disease-predisposing variations with nevirapine-induced rash using genome-wide single-nucleotide polymorphisms (SNPs) as genetic markers...
  59. doi request reprint Temporary external lumbar drainage for reducing elevated intracranial pressure in HIV-infected patients with cryptococcal meningitis
    Weerawat Manosuthi
    Department of Medicine, Bamrasnaradura Infectious Diseases Institute, Tiwanon Road, Nonthaburi 11000, Thailand
    Int J STD AIDS 19:268-71. 2008
    ..In resource-limited settings, the use of temporary external lumbar drainage is a safe and effective management strategy for intractable elevated ICP in HIV-infected patients with cryptococcal meningitis...
  60. ncbi request reprint Compliance with hepatitis B and hepatitis C virus infection screening among HIV-1 infected patients in a resource-limited setting
    Somnuek Sungkanuparph
    Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
    Southeast Asian J Trop Med Public Health 39:863-6. 2008
    ..8% had HCV infection. Given the relatively high prevalence of HBV and HCV infection among HIV-infected patients, screening for HBV and HCV infections prior to ART initiation should not be omitted in the resource-limited setting...
  61. ncbi request reprint High plasma efavirenz concentration and CYP2B6 polymorphisms in Thai HIV-1 infections
    Chonlaphat Sukasem
    Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University
    Drug Metab Pharmacokinet 28:391-7. 2013
    ..The genetic configuration of SNPs which are associated with high plasma efavirenz levels may be useful in optimizing the efavirenz dose that is used in HIV-1 infected patients. ..
  62. pmc CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1
    Weerawat Manosuthi
    Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand
    Antimicrob Agents Chemother 58:2268-73. 2014
    ..254). In summary, the CYP2B6 18492T→C polymorphism compromises efavirenz concentrations in patients who carry CYP2B6 haplotype *1/*1 and are coinfected with HIV and tuberculosis...
  63. ncbi request reprint Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study
    Somnuek Sungkanuparph
    Division of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
    J Med Assoc Thai 87:1349-54. 2004
    ..Information regarding prevalence of HBV and HCV co-infection with HIV in Thailand is limited...
  64. pmc Health related quality of life among patients with tuberculosis and HIV in Thailand
    Wanitchaya Kittikraisak
    Thailand Ministry of Public Health, U S Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand
    PLoS ONE 7:e29775. 2012
    ..Health utilities of tuberculosis (TB) patients may be diminished by side effects from medication, prolonged treatment duration, physical effects of the disease itself, and social stigma attached to the disease...
  65. pmc Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults
    Sumonmal Uttayamakul
    Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    AIDS Res Ther 7:8. 2010
    ..CONCLUSIONS: CYP2B6-TT genotype had impact on plasma efavirenz and nevirapine concentrations, while rifampicin co-administration had only small effects...
  66. pmc Virological failure of staggered and simultaneous treatment interruption in HIV patients who began Efavirenz-based regimens after allergic reactions to nevirapine
    Krittaecho Siripassorn
    Department of Internal Medicine, Bamrasnaradura Infectious Diseases Institute, 126 Tiwanon Road, Nonthaburi, 11000, Thailand
    AIDS Res Ther 10:4. 2013
    ..abstract:..
  67. ncbi request reprint Clinical experience with high success rate of antiretroviral therapy in elderly HIV-infected patients
    Somnuek Sungkanuparph
    Age Ageing 33:520-1. 2004
  68. doi request reprint Mortality rate of early versus deferred initiation of antiretroviral therapy in HIV-1-infected patients with cryptococcal meningitis
    Weerawat Manosuthi
    J Acquir Immune Defic Syndr 48:508-9. 2008
  69. ncbi request reprint Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir
    Weerawat Manosuthi
    J Acquir Immune Defic Syndr 47:127-9. 2008